Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2025)

ARS Pharmaceuticals' Change in Receivables history spans 2 years, with the latest figure at -$11.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 251.0% year-over-year to -$11.2 million; the TTM value through Dec 2025 reached $17.2 million, up 110.46%, while the annual FY2025 figure was $17.2 million, 110.46% up from the prior year.
  • Change in Receivables for Q4 2025 was -$11.2 million at ARS Pharmaceuticals, down from $14.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $14.0 million in Q3 2025 and bottomed at -$11.2 million in Q4 2025.